SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

msh id	COM:SCYNEXIS
symbol	SCYX
name	SCYNEXIS, Inc.
homepage url	https://www.scynexis.com
country	US
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	29
crunchbase url	-
linkedin url	-
founders	-

market cap	74.43M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.26
growth cost of revenue	25.17
growth depreciation and amortization	0.86
growth ebitda	1.86
growth ebitda ratio	1.03
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	26.72
growth gross profit ratio	0.01

COM:SCYNEXIS

SCYNEXIS, Inc.

Last Close

1.18

21/11 21:00

Market Cap

74.43M

Beta: -

Volume Today

103.17K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	67.47M
cost of revenue	67.47M
depreciation and amortization	810K
ebitda	73.48M
ebitda ratio	0.52
eps	1.4
eps diluted	1.39
operating expenses	51.04M
operating income	72.67M
operating income ratio	0.52

accounts receivables	-19.73M
capital expenditure	-
cash at beginning of period	45.87M
cash at end of period	34.43M
inventory	-
working capital ttm	111.85M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-